8 research outputs found
Evaluation and performance characteristics of the Q Hemostasis Analyzer, an automated coagulation analyzer
Development and implementation of tPA clot lysis activity assay using ACL TOPâą hemeostasis testing system in QC laboratories
Performance characteristics of the turbidimetric ACL-TOP CTS 300 coagulation analyzer in dogs and cats
Measurement of factor VIII activity using one-stage clotting assay: a calibration curve has not to be systematically included in each run
High Prevalence of Acquired Thrombophilia Without Prognosis Value in Patients With Coronavirus Disease 2019
International audienceBackgroundRecent literature reports a strong thrombotic tendency in patients hospitalized for a coronavirus disease 2019 (COVIDâ19) infection. This characteristic is unusual and seems specific to COVIDâ19 infections, especially in their severe form. Viral infections can trigger acquired thrombophilia, which can then lead to thrombotic complications. We investigate for the presence of acquired thrombophilia, which could participate in this phenomenon, and report its prevalence. We also wonder if these thrombophilias participate in the bad prognosis of severe COVIDâ19 infections.Methods and ResultsIn 89 consecutive patients hospitalized for COVIDâ19 infection, we found a 20% prevalence of PS (protein S) deficiency and a high (ie, 72%) prevalence of antiphospholipid antibodies: mainly lupus anticoagulant. The presence of PS deficiency or antiphospholipid antibodies was not linked with a prolonged activated partial thromboplastin time nor with Dâdimer, fibrinogen, or CRP (Câreactive protein) concentrations. These coagulation abnormalities are also not linked with thrombotic clinical events occurring during hospitalization nor with mortality.ConclusionsWe assess a high prevalence of positive tests detecting thrombophilia in COVIDâ19 infections. However, in our series, these acquired thrombophilias are not correlated with the severity of the disease nor with the occurrence of thrombotic events. Albeit the strong thrombotic tendency in COVIDâ19 infections, the presence of frequent acquired thrombophilia may be part of the inflammation storm of COVIDâ19 and should not systematically modify our strategy on prophylactic anticoagulant treatment, which is already revised upwards in this pathological condition